RecruitingPhase 2NCT06261489

Cannabis (THC vs. CBD) in Multiple Sclerosis

The Differential Effects of THC vs. CBD on Cognition in Persons With MS

Sponsor

University of Calgary

Enrollment

30 participants

Start Date

Dec 5, 2025

Study Type

INTERVENTIONAL

Conditions

Multiple Sclerosis

Summary

The goal of this clinical trial is to examine the effect of Cannabis components, THC and CBD, on cognition and bladder symptoms in people with Multiple Sclerosis (MS). Participants will complete questionnaires and cognitive tests. They will be randomly assigned to receive either CBD or THC oil and will take the study drug for 15 weeks.

Eligibility

Min Age: 26 YearsMax Age: 59 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CBD and a drug called THC for people with multiple sclerosis. The study is currently recruiting participants at 2 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTHC

Participants will be randomly assigned to the study treatment. THC dose will be gradually increased until 25 mg. Treatment will be taken orally at bedtime for 15 weeks.

DRUGCBD

Participants will be randomly assigned to the study treatment. CBD dose will be gradually increased until 50 mg. Treatment will be taken orally at bedtime for 15 weeks.